Form D · Biotechnology
Celldex Therapeutics, Inc.
Hampton, NJ · CIK 0000744218
Offering snapshot reported Nov 29, 2016 · SEC filing
- Reported sold
- $62.5M Offering amount: $62.5M
- Investors reported
- 29 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 29, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 29, 2016 | Initial | $62,500,000 | No comparison | 29 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-275294
Excludes milestone payments of up to $172.5 million which may be made in cash or shares or a combination thereof.
Source: Form D, filed Nov 29, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Avery W. Catlin | Executive |
| Herbert J. Conrad | Director |
| Larry Ellberger | Director |
| George O. Elston | Director |
| Anthony S. Marucci | Director, Executive |
| Harry H. Penner, Jr. | Director |
| Karen Shoos | Director |
| Richard Van Den Broek | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
53 Frontage Road, Suite 220
Hampton, NJ, 08827
Hampton, NJ, 08827